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Objective. Platelet-rich fibrin (PRF) clots andmembranes are autologous blood concentrates widely used in oral surgical procedures;
less is known, however, about the liquid formulations of such products. The aim of this in vitro study is to assess the behavior
of different implant surfaces when in contact with two liquid leucocyte- and platelet-rich fibrin (L-PRF) products. Methods. Six
commercial pure titanium discs, of 9.5mm diameter and 1.5mm thickness, were used. Three of these samples had a micro/nano-
rough surface; three were machined. Three different protocols were tested. Protocols involved the immersion of the samples in (1)
a platelets, lymphocytes, and fibrinogen liquid concentrate (PLyF) for 10 minutes, (2) an exudate obtained from L-PRF clots rich
in fibronectin and vitronectin for 5 minutes, and (3) the fibronectin/vitronectin exudate for 2 minutes followed by immersion in
the PLyF concentrate for further 8 minutes. After these treatments, the samples were fixed and observed using a scanning electron
microscope (SEM). Results. Under microscopic observation, (1) the samples treated with the PLyF concentrate revealed a dense
fibrin network in direct contact with the implant surface and a significant number of formed elements of blood; (2) in the samples
treated with the fibronectin/vitronectin exudates, only a small number of white and red blood cells were detectable; and (3) in
samples exposed to the combined treatment, there was an apparent increase in the thickness of the fibrin layer. When compared to
the machined surface, the micro/nano-rough samples showed an overall increased retention of fibrin, leading to a thicker coating.
Conclusions. Liquid L-PRF products promote the formation of a dense fibrin clot on micro/nano-rough implant surfaces in vitro.
The adjunctive treatment of surfaces with the fibronectin/vitronectin exudate could provide support to contact of the fibrin with
the surface, though it is not essential for the clot formation. Further studies are necessary to better elucidate the properties and
benefits of liquid L-PRF products.
1. Introduction
Implant supported oral rehabilitation has increasingly
improved the treatment options for edentulous patients,
reporting high long-term survival and success rates [1, 2].
However some clinical conditions can affect osseointegration,
significantly reducing the success rate of dental implants. An
increased rate of implant loss has been reported in irradiated
patients [3], in patients receiving bisphosphonates [4], and
in individuals with severe periodontal disease [5]. In these
patients, implant failures can occur at an early stage of
peri-implant bone healing, thus suggesting a role for local
factors. One fundamental phase of the healing process is the
formation of a stable fibrin clot in contact with the implant
surface to provide a provisional scaffold for the migration of
differentiating osteogenic cells towards the implant surface
[6]. This has led to the development of surfaces with specific
micro- and nanotopographies and biomimetic characteristics
to promote fibrin adhesion and improve osseointegration.
If, on the one hand, dental implants with surface micro-
topography have become a standard of care, on the other very
fewbrands commercially offermicro-nano-textured surfaces,
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whilst biomimetic approaches for implant functionalization
are still not available for clinical use. These treatments
generally involve immobilization of specific peptides on the
implant surface during the production process. Another
possible approach involves functionalizing the implant
surface with the patient’s autologous blood immediately
before placement.
Today, platelet concentrates include several biologic
products, commonly referred to as platelet-rich plasma (PRP)
and platelet-rich fibrin (PRF), used to facilitate and promote
wound healing. Specific formulations also include leucocyte-
and platelet-rich fibrin (L-PRF) products [7]. Platelet con-
centrates are obtained through the centrifugation of a whole
blood sample, discarding red blood cells and concentrating
the components of use for therapeutic purposes, that is,
fibrinogen, fibrin, platelets, growth factors, leukocytes, and
other circulating cells [8, 9]. By pressing the fibrin clots
obtained through the centrifugation, an exudate is formed
which is rich in growth factors and serum proteins, including
fibronectin and vitronectin [10]. These play an important
role in cell adhesion and migration into the fibrin clot [11].
Liquid concentrates rich in platelets, lymphocytes, plasma
proteins, andfibrinogen can also be obtained by shorter blood
centrifugation. This plasma fibrinogen concentrate can be
collected before coagulation and used for local delivery of
growth factors similarly to the clots. Compared to PRF clots
however, less is known as to the properties and the potential
applications of liquid PRF products.
Although platelet concentrates are widely used in bone
regeneration procedures, their role in relation to implant
osseointegration remains poorly investigated. The purpose
of this in vitro study was thus to evaluate the effects of
treating rough and smooth implant surfaces with two liquid
leucocyte- and platelet-rich fibrin (L-PRF) products.
2. Materials and Methods
2.1. Liquid Platelet Concentrate and Exudate Preparation.
Blood samples (9 cc each) were collected in 6 red cap vacuum
tubes (IntraSpin, Intra-Lock International, Boca Raton,
FL) to obtain the L-PRF clots and two white cap vacuum
tubes (IntraSpin, Intra-Lock International, Boca Raton, FL)
to produce the liquid concentrate. The total of 8 test tubes
was then placed within the centrifuge (IntraSpin, Intra-
Lock International, Boca Raton, FL) at opposing positions
to balance the rotor (Figure 1(a)). After 3 minutes of cen-
trifugation at 2700 rpm, the process was stopped and the
2 white tubes were removed, and the centrifuge restarted
for a remaining period of 9 minutes. 3 cc of liquid (PLyF
concentrate) was taken from the top of test tubes with the
white caps (Figure 1(b)). After a total of 12 (3 + 9) minutes
of centrifugation at 2700 rpm, the L-PRF clots were removed
from the test tubes. The red layer containing the red blood
cells was gently separated using a sterile instrument.The clots
were then placed on a sterile metal grid and compressed
under the weight of a sterile metal plate (Figure 1(c)), without
applying any manual pressure (Xpression Kit, Intra-Lock
International, Boca Raton, FL). After 5 minutes the L-PRF
membranes were formed and the expressed exudate rich in
fibronectin and vitronectin was collected at the base of the
metal box (Figure 1(d)).
2.2. Treatment of Titanium Discs. Twelve sterile commercial
pure titanium discs (ASTM Grade 4) of 9.5mm diameter
and 1.5mm thickness were used for this study. Six discs had
a rough fractal nanosurface (Ossean surface, Intra-Lock
International, Boca Raton, FL, USA) and six a machined
surface. The discs were then divided into three separate
groups using a multiwell cell culture plate: four discs, two
machined and two rough (PR and PL), were immersed
in the PLyF concentrate for 10 minutes; four discs, two
machined and two rough (ER and EL), were immersed in
the fibronectin and vitronectin exudate for 5 minutes; four
discs, two machined and two rough (EPR and EPL), were
first immersed in the fibronectin and vitronectin exudate for
2 minutes and then in the PLyF liquid for 8 minutes. The
samples were then fixed with 2% glutaraldehyde in 0.1M
cacodylate buffer (pH 7.4) and successively analyzed using
a field emission gun scanning electron microscope (FEG-
SEM) (Inspect FTM, FEI Company, Hillsboro, OR, USA) at
different magnifications and an acceleration voltage of 10 kV.
3. Results
On microscopic analysis, the PR samples revealed a high-
density, small-meshed fibrin network (Figures 2(a)–2(d)). A
significant number of red blood cells, white blood cells, and
platelets were also observed, both in contact with the disc
surface and within the fibrin network. The fibrin clot was
of variable thickness and direct contact between the fibrin
network and the implant surface could be observed. Partial
detachment of the fibrin from the titanium surface was also
noted in some areas of the sample.
In samples PL a wide-meshed fibrin network was
observed (Figures 2(e)–2(h)). As compared to PR, the fib-
rin layer had a reduced thickness with few contact points
between the fibrin and the implant surface. Similarly to PR
samples, a number of blood cells and platelets were trapped
in the fibrin network.
In samples ER (Figures 3(a)–3(d)) and EL (Figures
3(e)–3(h)) no significant biologic process could be observed.
Few white and red blood cells could be identified in contact
with surface irregularities.
Similarly to what was observed in the PR samples, a
dense, small-meshed fibrin layer had formed on the EPR discs
(Figures 4(a)–4(d)). Compared to PR, a greater quantity of
fibrin had formed and a relatively higher number of formed
blood elements were also detected within the fibrin clot.
Several areas showed partial or total detachment of the fibrin
layer from the surface, probably occurring during the fixation
process.
Finally, the EPL samples were covered with a wide-
meshed fibrin network with several formed blood elements
(Figures 4(e)–4(h)). Compared to EPR, the fibrin layer onEPL
showed a reduced thickness in all the observed areas. Sim-
ilarly to PL, few direct contacts between the fibrin network
and the implant surface were identified.
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Figure 1: L-PRF products preparation. (a) The centrifuge used for the study with the vacutainer tubes in place. (b) PLyF concentrate on the
top of the white vacutainer. (c) L-PRF membranes obtained after compression of the clots. (d) Exudate rich in fibronectin and vitronectin
derived from membranes compression.
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 2: SEM images of titanium samples after immersion in the PLyF concentrate for 10 minutes. (a–d) Samples with rough surface (PR).
(e–h) Samples with machined surface (PL). A dense fibrin network has formed on the surfaces with abundant thrombocytes, erythrocytes,
and leukocytes.
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Figure 3: SEM images of titanium samples after immersion in the fibronectin and vitronectin exudate for 5minutes. (a–d) Samples with rough
surface (ER). (e–h) Samples with machined surface (EL). Scarce erythrocytes and leukocytes can be clearly detected on both the surfaces.
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 4: SEM images of titanium samples after immersion in the fibronectin and vitronectin exudate for 2 minutes and then in the PLyF
concentrate for further 8 minutes. (a–d) Samples with rough surface (EPR). (e–h) Samples with machined surface (EPL). Compared to PR
and PL samples, a major quantity of fibrin has formed on the surfaces.
4. Discussion
The results of this study have shown that the contact of
a micro/nano-rough implant surface with a liquid blood
concentrate allows formation of a stable fibrin layer con-
taining platelets and leucocytes. SEM micrographs have also
suggested that fibrin clot formationmay be further supported
by adjunctive pretreatment of samples with an exudate
containing fibronectin and vitronectin.
Platelet concentrates have been used widely in several
branches of medicine to improve repair of soft tissue. In
recent years, particular attention has been given to the
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potential for interaction between platelet concentrates and
bone healing. In an experimental rat model of femoral
fracture, Du¨lgeroglu and Metineren [12] observed increased
bone formation after 28 days of healing when PRF clots
were applied to bone. Similarly, Nagata et al. [13] observed
significantly increased bone formation in surgically created
bone defects in rat calvaria treated with a combination of
autogenous bone graft and platelet-rich plasma. In 2003,
Schlegel et al. [14] tested the potential of PRP in artificial
peri-implant bone defects in a dog model without conclusive
results. Most recent research has focused on the use of PRF
to enhance bone regeneration and osseointegration. PRF
has proven effective in bone regeneration of peri-implant
defects in both animal [15, 16] and human clinical studies
[17, 18]. In a histometric study in rabbits, O¨ncu¨ et al. [19]
evaluated the effect on osseointegration of placing L-PRF
within implant beds and implant prewetting in L-PRF clots
before placement.The authors report increases in the rate and
the amount of new bone formation in the experimental group
compared to the control, especially in the early healing stages.
In a histologic study in dogs, Neiva et al. [20] evaluated the
effects of L-PRF around immediately placed implants with
two different surfaces, micro/nano-rough surface (Ossean
surface) and dual-etched.The authors reported a significantly
increased bone formation by combining Ossean surface with
L-PRF concluding thatmicro/nano-rough surface and L-PRF
have a synergistic effect on peri-implant bone healing.
In the present study a different approach has been
developed, consisting in soaking the titanium samples in a
liquid platelet concentrate obtained after 3 minutes of cen-
trifugation. The theoretical advantage of liquid concentrates
instead of PRF clots is that fibrin polymerization occurs in
direct contact with the implant surface. As demonstrated by
the SEM images, fibrin can establish numerous contacts with
the implant surface, providing a biologic coating. Although
various efforts are being made to improve osseointegration
by mechanisms such as implant surface coating, the most
important biological event is the fibrin clot formation around
the implant. The quality and stability of the fibrin clot are,
in fact, a prerequisite for mesenchymal stem cell migration
and differentiation into the osteoblast lineage and subse-
quent contact osteogenesis. From this perspective, L-PRF
concentrates provide all the key agents necessary for the
early stages of osseointegration: fibrin, platelets (and related
growth factors), and leukocytes.
Bone healing is also influenced by a number of molecules
including fibronectin and vitronectin. During the early heal-
ing phase, fibronectin is incorporated into the fibrin matrix
affecting distinct platelet functions (adhesion aggregation,
activation), as well as cell migration into the forming pro-
visional matrix [21, 22]. Similarly, once incorporated into
the fibrin clot vitronectin supports platelet adhesion and
aggregation and, at later stages, contributes to cell adhesion
to the extracellular matrix [23]. Based on this, some authors
have proposed fibronectin and vitronectin-coated implants
to enhance osseointegration [24–26]; despite some positive
results obtained in vitro, however, the complexity and cost
of such surface treatments have limited their widespread use.
In this study, a simpler approach, consisting in soaking the
surfaces in the L-PRF-derived products, has been adopted.
In the case of the fibronectin/vitronectin exudate, protein
adsorption occurs as a result of van der Waals forces or
electrostatic interactions similarly to what happens in vivo.
Moreover, in adjunction to the autologous origin of adsorbed
molecules, the advantage of this procedure is that it is
applicable during surgery [27].
The use of PRF preparations for the biomimetic coating of
dental implants can promote peri-implant bone healing also
through the local delivery of growth factors and proteins [28].
Various growth factors, including platelet-derived growth
factor (PDGF) and transforming growth factor beta (TGF-
𝛽), are secreted by local platelet degranulation. Growth
factors act as modulators of cellular activity, inducing specific
responses in all phases of bone repair [29] and promoting
angiogenesis [30]. From this perspective, PRF products may
have an osteopromotive effect during peri-implant bone
healing when associated with a nanotextured surface [31, 32].
Indeed, the specific L-PRF formulation used in this study
could further support the healing process, participating in the
initial inflammatory response.However the role of leukocytes
contained in PRF still has to be elucidated.
Considering these properties, PRF products may find
application in patients with impaired bone healing capacity,
for example, those who have undergone radiation therapy.
In these patients, osseointegration is negatively affected as a
result of the hypocellular, hypovascular, and hypoxic tissue
environment [33], with an increased risk of failure particu-
larly in the maxilla and in grafted sites [34]. These products
could also prove beneficial in immediate implant placement
after extraction, to stimulate fibrin clot formation in the gap
between the alveolar bone and the implant surface, in guided
bone regeneration procedures with simultaneous implant
placement [35], and in the regeneration of peri-implant
defects [36]. However, rather than as hitherto described
in the literature, this study proposes use of liquid L-PRF
instead of clots in order to enhance direct contact of the
fibrin layer with the implant surface, obtaining an immediate
biofunctionalization of the surface.
5. Conclusion
This study represents a preliminary evaluation of surface
treatment with liquid L-PRF products, with the main limi-
tations being a small number of samples and the qualitative
nature of the observations. The study results indicate that
treatment of implant surfaces with liquid PRF leads to
the formation of a stable and dense fibrin layer in direct
contact with the implant surface, thus providing a biomimetic
autologous coating. Compared to machined surfaces, the
micro/nano-rough samples were found to be more retentive,
leading to thicker coatings. Adjunctive treatment with the
L-PRF clot exudate containing fibronectin and vitronectin
seems to promote greater fibrin adhesion and formation
when in combination with the liquid platelet concentrate.
There is a need for additional studies to better elucidate
the potential benefits of liquid PRF in enhancing osseoin-
tegration, particularly in those patients for whom implant
therapies still encounter increased risk of failure.
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